연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3855. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S
ESMO Open 10(11):105858.
Link
3854. Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Saura C, Cortés J, Modi S, Kim SB, Hamilton E, Hurvitz SA, Krop IE, Curigliano G, Iwata H, Im SA, Herbolsheimer P, Karnoub M, Boran A, Kuwahara Y, Egorov A, André F
Annals of oncology [Epub ahead of print]
Link
3853. Correction: Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study
Shin E, Kim SI, Park MH, Kim HA, Jung Y, Ryu JM, Park EH, Kim SY, Lee EG, Lee MH, Park JH, Im SA, Bae SJ, Kang SH, Lim WS, Youn HJ, Park HK, Park KH, Kim TH, Park SY, Lim CW, Kwak GH, Park C, Shin HJ, Yoo YB, Kang SH, Kim BK, Kim HJ
Frontiers in oncology 7:15:1729229.
Link
3852. Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach
Jung S, Kim J, Lee SH, Shin JS, Kim WH, Jung D, Kim TY, Im SA, Lee KH, Hahm BJ, Yeom CW
Supportive care in cancer 33(11):945
Link
3851. Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study
Shin E, Kim SI, Park MH, Kim HA, Jung Y, Ryu JM, Park EH, Kim SY, Lee EG, Lee MH, Park JH, Im SA, Bae SJ, Kang SH, Lim WS, Youn HJ, Park HK, Park KH, Kim TH, Park SY, Lim CW, Kwak GH, Park C, Shin HJ, Yoo YB, Kang SH, Kim BK, Kim HJ
Frontiers in oncology 15:1465256
Link
3850. Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy
Cortes J, Lipatov O, Im SA, Goncalves A, Lee KS, Schmid P, Tamura K, Testa L, Ohtani S, Harbeck N, Loi S, Salgado R, Karantza V, Mejia J, Cristescu R, Loboda A, Nebozhyn M, Jelinic P, Huang L, Winer EP
NPJ breast cancer 11(1):109.
Link
3849. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Modi S, Jacot W, Iwata H, Park YH, Vidal Losada M, Li W, Tsurutani J, Ueno NT, Zaman K, Prat A, Papazisis K, Rugo HS, Yamashita T, Harbeck N, Im SA, De Laurentiis M, Pierga JY, Wang X, Gombos A, Tokunaga E, Orbegoso Aguilar C, Yung L, Xiao F, Cheng Y, Cameron D
Nature medicine 31(12):4205-4213
Link
3848. Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial
Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA.
JAMA oncology 11(11):1364-1372.
Link
3847. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy
Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F
Annals of oncology 36(7):832-837.
Link
3846. Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
Ahn HK, Kim JH, Koh SJ, Sohn J, Kang MJ, Jung KH, Lee KE, Lee J, Koh SA, Chae YS, Byun JH, Park IH, Kim HJ, Kim JH, Kim HJ, Jung JY, Lee JL, Cho YY, Park KH, Kim JY, Im SA, Park YH.
The Lancet regional health. Western Pacific 60:101622.
Link